Bionano Genomics, Inc. Stock price

Equities

BNGO

US09075F3055

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.11 USD +1.83% Intraday chart for Bionano Genomics, Inc. +5.71% -41.27%
Sales 2024 * 38.74M Sales 2025 * 50.93M Capitalization 59.62M
Net income 2024 * -87M Net income 2025 * -69M EV / Sales 2024 * 1.54 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.17 x
P/E ratio 2024 *
-0.58 x
P/E ratio 2025 *
-0.86 x
Employees 344
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.52%
More Fundamentals * Assessed data
Dynamic Chart
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance CI
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating MT
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Bionano Genomics, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
Bionano Genomics, Inc. announced that it has received $35 million in funding CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 CI
Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via? Software for Ogm Data Analysis in Constitution Genetic Disease Research CI
Bionano Genomics, Inc. Announces Publication of Largest Prospective Prenatal Study Comparing Ogm to Chromosomal Microarray Analysis and Karyotyping CI
North American Morning Briefing : Caution -2- DJ
Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
More news
1 day+4.81%
1 week+3.81%
Current month-12.80%
1 month-16.15%
3 months-48.10%
6 months-62.80%
Current year-42.33%
More quotes
1 week
1.02
Extreme 1.02
1.14
1 month
1.00
Extreme 1
1.34
Current year
1.00
Extreme 1
2.16
1 year
1.00
Extreme 1
11.80
3 years
1.00
Extreme 1
91.20
5 years
1.00
Extreme 1
156.90
10 years
1.00
Extreme 1
156.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 11-01-11
Director of Finance/CFO 51 23-09-10
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 64 18-06-30
Chairman 82 10-05-10
Director/Board Member 75 11-09-30
More insiders
Date Price Change Volume
24-03-28 1.11 +1.83% 1 717 941
24-03-27 1.09 +4.81% 1,742,588
24-03-26 1.04 +0.97% 737,761
24-03-25 1.03 -0.96% 1,249,009
24-03-22 1.04 -1.89% 707,114

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.09 USD
Average target price
6.667 USD
Spread / Average Target
+511.62%
Consensus
  1. Stock
  2. Equities
  3. Stock Bionano Genomics, Inc. - Nasdaq